Opinion|Videos|July 18, 2024
NCCN Guidelines Revisions and ASCO 2024 Research Outlook
An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.
Advertisement
Episodes in this series
- How do you think the revised NCCN Guidelines for breast cancer will impact patient outcomes?
- What data, results, or insights are you looking forward to coming out of ASCO 2024?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV
2
New Bill Would Cap Traditional Medicare Out-of-Pocket Costs at $5000
3
Topical Delgocitinib Improves Chronic Hand Eczema Outcomes Across All Trial Timepoints
4
FDA Expands Risankizumab Approval to Pediatric Plaque Psoriasis, Active PsA
5